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ABSTRACT
Background: The CCR5Δ32 polymorphism (a naturally occurring 32-bp deletion in CCR5) influences the
ability of HIV-1 to infect the target cells. Homozygosity for CCR5Δ32 prevents infection of HIV-1 R5 strain,
while the heterozygous is associated with lower plasma viral load and delayed progression to acquired
immune deficiency syndrome (AIDS). However, there is no report about the presentation of CCR5Δ32
polymorphisms in Indonesian HIV patients. The aim of this study is to detect CCR5Δ32 polymorphisms in
Indonesian HIV patients, especially in Voluntary Counseling and Testing Moewardi General Hospital Surakarta,
Indonesia. In an ongoing molecular epidemiology study of blood borne virus, 154 HIV patients in Moewardi
General Hospital Surakarta were used for the study. The blood samples were collected during November –
December 2011. The blood samples were aliquoted and fractionated. The DNA was extracted from all blood
samples, and subjected for the PCR assay to detect the presentation of CCR5Δ32 polymorphisms. Internal
amplification control was included in all assays. PCR products were analyzed in 3% agarose. The results
showed that CCR5Δ32 polymorphism was not detected in all blood samples. So it can be concluded that all
patients in this study had the CCR5 wild type.
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INTRODUCTION
Human immunodeficiency virus (HIV) entry into target cells is a multi-step process in-
volving binding of the viral glycoprotein, Env, to its receptor CD4 and a co-receptor of CCR5
or CXCR4. Understanding the means by which HIV enters cells has led to the identification
of the CCR5Δ32 polymorphism that confers resistance to infection in homozygous individuals,
and has also resulted in the development of entry inhibitors-small molecule antagonists that
block infection at the entry step (Didigu & Doms, 2012; Grivel et al., 2011). A natural deletion
of 32 bases in CCR5 (CCR5Δ32) gene resulting in truncated protein product (Liu et al.,
2012). People homozygous for CCR5Ä32 are naturally resistant to R5 HIV infection and the
heterozygous state is associated with up to 2–4 years delay in disease progression (Gupta
& Padh, 2012). This polymorphism was found in Caucasians and in Chinese state high
(Liu et al., 2012) and exists at allele frequencies of typically 10% in European populations
(Hyde et al., 2010). However, to our knowledge, the presence of CCR5Δ32 polymorphisms
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in Indonesian HIV patients has not been reported. The research aims to detect the CCR5Δ32
polymorphism in HIV patients in Indonesia, especially in Surakarta, Indonesia.
MATERIALS AND METHODS
In November – December 2011, HIV patients from Surakarta and its surrounding area
of Voluntary Counseling and Testing Moewardi General Hospital Surakarta (n= 154) were
invited for the ongoing blood borne virus molecular epidemiology study. The ethical issues of
this blood sample collection had been approved by the institutional ethical committee review
boards of the Faculty of Medicine of Sebelas Maret University and Dr. Moewardi General
Hospital, Surakarta, Indonesia. Blood samples collected from the patients were fraction-
ated, aliquoted and kept frozen until further analysis. All the procedures were conducted
according to the principles of the Declaration of Helsinki.
The nucleic acid was extracted from all blood samples using High Pure PCR Template
Preparation Kits (Roche Diagnostic, Mannheim, Germany) and subjected for the PCR as-
say to detect the presence of CCR5Δ32 polymorphisms using primer set as described pre-
viously (Huang et al., 1996), by Amplitaq Gold® 360 DNA Polymerase Kit (Invitrogen,
Carlsbad, CA). Human β-globin was included as internal amplification control in all assays.
PCR products were analyzed in 3% Agarose.
RESULTS AND DISCUSSION
Using the primer set used the length for CCR5 wild type is 189 bp, but for CCR5Δ32 is
157 bp (Huang et al., 1996). The human β-globin PCR product is 100 bp and used as inter-
nal amplification control to exclude the false negative results. All genomic DNA were suc-
cessfully isolated and amplified, showed by the presentation of two expected bands in 3%
agarose after electrophoresis, 100 bp and 189 bp bands, and no sample showed 100 bp
and 157 bp bands. Therefore, in this present study, all patients in the study had the CCR5
wild type, and no CCR5Δ32 polymorphism was detected. Our results indicated that CCR5Δ32
polymorphism maybe not exist in Indonesia population, at least in HIV patients involved in
the study. However, due to small number of patients enrolled in the study and only HIV pa-
tients from Surakarta and its surrounding area were assayed in the present study, a bigger
and more adequate sampling method is needed to clarify the presentation of CCR5Δ32
polymorphism in Indonesian.
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